BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 536 filers reported holding BIO-TECHNE CORP in Q1 2023. The put-call ratio across all filers is 0.40 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $719,160 | -19.2% | 10,565 | -3.1% | 0.02% | -11.1% |
| Q2 2023 | $889,767 | -39.6% | 10,900 | -45.1% | 0.02% | -40.0% |
| Q1 2023 | $1,473,710 | -13.1% | 19,864 | -2.9% | 0.03% | -14.3% |
| Q4 2022 | $1,695,891 | -29.1% | 20,462 | +143.1% | 0.04% | -30.0% |
| Q3 2022 | $2,391,000 | -20.7% | 8,418 | -3.2% | 0.05% | -12.3% |
| Q2 2022 | $3,014,000 | -38.0% | 8,695 | -22.6% | 0.06% | -24.0% |
| Q1 2022 | $4,864,000 | -3.3% | 11,233 | +15.5% | 0.08% | +4.2% |
| Q4 2021 | $5,032,000 | +23.7% | 9,727 | +15.9% | 0.07% | +16.1% |
| Q3 2021 | $4,067,000 | +25.6% | 8,393 | +16.7% | 0.06% | +29.2% |
| Q2 2021 | $3,238,000 | +16.0% | 7,191 | -1.6% | 0.05% | +11.6% |
| Q1 2021 | $2,792,000 | +61.2% | 7,310 | +34.0% | 0.04% | +48.3% |
| Q4 2020 | $1,732,000 | +82.3% | 5,454 | +42.2% | 0.03% | +61.1% |
| Q3 2020 | $950,000 | -57.1% | 3,835 | -54.3% | 0.02% | -58.1% |
| Q2 2020 | $2,217,000 | +48.6% | 8,396 | +6.7% | 0.04% | +22.9% |
| Q1 2020 | $1,492,000 | -16.6% | 7,868 | -3.5% | 0.04% | +12.9% |
| Q4 2019 | $1,790,000 | +8.4% | 8,156 | -3.3% | 0.03% | +3.3% |
| Q3 2019 | $1,651,000 | -38.2% | 8,436 | -34.2% | 0.03% | -37.5% |
| Q2 2019 | $2,672,000 | +18.8% | 12,814 | +13.1% | 0.05% | +20.0% |
| Q1 2019 | $2,249,000 | +35.5% | 11,325 | -1.2% | 0.04% | +21.2% |
| Q4 2018 | $1,660,000 | -27.7% | 11,467 | +2.0% | 0.03% | -13.2% |
| Q3 2018 | $2,296,000 | +106.5% | 11,247 | +49.7% | 0.04% | +100.0% |
| Q2 2018 | $1,112,000 | +36966.7% | 7,515 | +41650.0% | 0.02% | – |
| Q1 2018 | $3,000 | -96.8% | 18 | -98.0% | 0.00% | -100.0% |
| Q4 2016 | $93,000 | -59.6% | 900 | -57.1% | 0.00% | -50.0% |
| Q3 2016 | $230,000 | -10.2% | 2,099 | -7.5% | 0.00% | 0.0% |
| Q2 2016 | $256,000 | +18.5% | 2,268 | -0.7% | 0.00% | 0.0% |
| Q1 2016 | $216,000 | +4.3% | 2,283 | -0.8% | 0.00% | +33.3% |
| Q4 2015 | $207,000 | -36.1% | 2,301 | -34.3% | 0.00% | -40.0% |
| Q3 2015 | $324,000 | -4.7% | 3,503 | +1.6% | 0.01% | 0.0% |
| Q2 2015 | $340,000 | +209.1% | 3,448 | +213.5% | 0.01% | +400.0% |
| Q1 2015 | $110,000 | +7.8% | 1,100 | 0.0% | 0.00% | 0.0% |
| Q4 2014 | $102,000 | – | 1,100 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 300,000 | $24,489,000 | 21.05% |
| Montanaro Asset Management Ltd | 388,800 | $31,737,744 | 5.02% |
| Sandhill Capital Partners LLC | 502,447 | $41,014,775 | 3.74% |
| Brown Capital Management | 3,160,892 | $258,023,614 | 3.66% |
| DF DENT & CO INC | 3,275,617 | $267,388,640 | 3.62% |
| Ownership Capital B.V. | 2,282,104 | $186,288,150 | 3.26% |
| Jackson Square Partners, LLC | 1,361,789 | $111,162,836 | 3.24% |
| STONE RUN CAPITAL, LLC | 88,135 | $7,194,460 | 3.20% |
| Pembroke Management, LTD | 339,591 | $27,720,813 | 2.99% |
| Summit Creek Advisors LLC | 283,693 | $23,157,860 | 2.90% |